Rösler N, Reuner C, Geiger J, Rissler K, Cramer H
Department of Neurology, University of Freiburg, F.R.G.
Peptides. 1990 Jan-Feb;11(1):181-3. doi: 10.1016/0196-9781(90)90129-s.
Cerebrospinal fluid (CSF) levels of substance-P like immunoreactivity (SPLI) and somatostatin-like immunoreactivity (SLI) were measured in 43 patients with multiple sclerosis (MS), differentiated according to course and activity of the disease, in 23 patients with inflammatory disease of known bacterial or viral etiology and in 16 control patients using specific radioimmunoassay. SPLI and SLI levels were not significantly different from controls in MS patients whereas SLI was significantly increased in patients with infectious disease of central nervous system and/or subarachnoidal space. It is assumed that CSF SPLI and SLI cannot serve as a diagnostic or prognostic indicator of disease state in multiple sclerosis. Analysis of immunoreactivity by reverse phase HPLC-RIA revealed marked molecular heterogeneity of both neuropeptides.
采用特异性放射免疫分析法，对43例多发性硬化症（MS）患者、23例已知细菌或病毒病因的炎症性疾病患者以及16例对照患者的脑脊液（CSF）中P物质样免疫反应性（SPLI）和生长抑素样免疫反应性（SLI）水平进行了检测。MS患者的SPLI和SLI水平与对照组无显著差异，而中枢神经系统和/或蛛网膜下腔感染性疾病患者的SLI显著升高。据推测，脑脊液中的SPLI和SLI不能作为多发性硬化症疾病状态的诊断或预后指标。通过反相高效液相色谱-放射免疫分析法对免疫反应性进行分析，结果显示这两种神经肽均存在明显的分子异质性。
